side-area-img-1
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis Theme

1-677-124-44227

[email protected]

184 MAIN COLLINS STREET WEST VICTORIA 8007

FOLLOW US ON INSTAGRAM
Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies

The No.1 Research Site For Therapeutic Peptides

Mobile Logo
Top

ARA-290 8mg

INTRODUCING

ARA-290 8mg

ARA-290 is a synthetic peptide derived from the naturally occurring erythropoietin (EPO). Unlike EPO, ARA-290 does not stimulate red blood cell production, but it retains the tissue-protective and anti-inflammatory properties of EPO. ARA-290 is an 11-amino acid peptide that has been investigated for its potential therapeutic effects in various medical conditions, including peripheral neuropathy, kidney injury, and inflammatory diseases.

Previous and ongoing research on ARA-290 has focused on several key areas:

  1. Neuropathy: ARA-290 has been studied for its potential neuroprotective and regenerative effects in peripheral neuropathy, particularly in the context of diabetes and chemotherapy-induced neuropathy.
  2. Kidney injury: ARA-290 has demonstrated potential therapeutic effects in animal models of acute kidney injury and chronic kidney disease, and its anti-inflammatory and tissue-protective properties may contribute to its renal benefits.
  3. Inflammatory diseases: ARA-290 has been investigated for its potential anti-inflammatory effects and its ability to modulate immune response, with potential applications in conditions such as rheumatoid arthritis and inflammatory bowel disease.

Current research on ARA-290 is focused on further understanding its mechanisms of action, optimizing its therapeutic applications, and investigating its safety and efficacy in various populations and medical conditions. Some recent research papers related to ARA-290 include:

  1. Heij, L., et al. (2017). “Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.” Molecular Medicine, 23, 1-8. [This study evaluates the safety and efficacy of ARA-290 in sarcoidosis patients with symptoms of small fiber neuropathy.]
  2. Brines, M., & Cerami, A. (2012). “The receptor that tames the innate immune response.” Molecular Medicine, 18, 486-496. [This review paper discusses the role of the innate repair receptor, which is targeted by ARA-290, in modulating the innate immune response.]
  3. Collino, M., et al. (2011). “Treatment with the Erythropoietin-derived Peptide ARA290 Improves Systolic Function and Reduces Ventricular Fibrosis in Rats with Ischaemic Heart Failure.” Journal of Pharmacy and Pharmacology, 63(4), 535-542. [This study investigates the potential effects of ARA-290 on systolic function and ventricular fibrosis in rats with ischemic heart failure.]

Peptides are the future of medicine. They are potent, tissue specific and effective at treating a variety of conditions with little to no side effects.

Dean Henry
Function Medicine Coach and Health Optimiser

Peptides are the next frontier in biohacking and performance enhancement. They can boost muscle growth, accelerate fat loss, improve sleep, increase energy and focus, and promote overall health and longevity.

Ben Greenfield
Biohacker and Health Expert

Peptides are tiny chains of amino acids that have powerful effects on the brain and body. They can improve memory, focus, and mood, and have anti-anxiety and anti-depressant effects.

Dr. Andrew Huberman, PhD
Professor of Neurobiology at Stanford University